---
title: "SUNHERE: Wholly-owned subsidiary Hefei SUNHERE won the land use rights"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/224437118.md"
description: "SUNHERE's wholly-owned subsidiary Hefei Sunhere Pharmaceutical Technology Co., Ltd. successfully obtained the land use rights for the TC4-3-2 plot in the High-tech Zone of Hefei City, Anhui Province. The land area is 13,100 square meters, with a lease term of 50 years and a total land price of 5.0131 million yuan. This plot will be used to build the Hefei R&D center and production base, aiming to enhance R&D innovation capabilities and optimize product structure. The funding source is the company's own funds, which will not affect the company's business independence and financial status"
datetime: "2025-01-09T11:11:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/224437118.md)
  - [en](https://longbridge.com/en/news/224437118.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/224437118.md)
generator: "portal-rs"
---

# SUNHERE: Wholly-owned subsidiary Hefei SUNHERE won the land use rights

SUNHERE announced that its wholly-owned subsidiary, Hefei Sunhere Pharmaceutical Technology Co., Ltd., recently participated in the bidding for the land use rights of the TC4-3-2 plot in the High-tech Zone of Hefei City, Anhui Province, and has signed the "State-owned Construction Land Use Rights Transfer Contract" with the Hefei Municipal Bureau of Planning and Natural Resources. The land area of the plot is 13,100 square meters, designated for industrial use, with a transfer period of 50 years, and the total land price is 5.0131 million yuan. Hefei Sunhere will use this plot to build a research and development center and production base in Hefei, aiming to enhance research and development innovation capabilities, optimize product structure, and achieve a strategic layout in the high-end pharmaceutical excipients market. The funds for purchasing the land use rights will come from the company's own funds and will not affect the company's business independence and financial status

### Related Stocks

- [300452.CN](https://longbridge.com/en/quote/300452.CN.md)
- [688603.CN](https://longbridge.com/en/quote/688603.CN.md)
- [688507.CN](https://longbridge.com/en/quote/688507.CN.md)
- [600721.CN](https://longbridge.com/en/quote/600721.CN.md)
- [600998.CN](https://longbridge.com/en/quote/600998.CN.md)
- [301096.CN](https://longbridge.com/en/quote/301096.CN.md)
- [300267.CN](https://longbridge.com/en/quote/300267.CN.md)
- [301252.CN](https://longbridge.com/en/quote/301252.CN.md)
- [002003.CN](https://longbridge.com/en/quote/002003.CN.md)
- [002727.CN](https://longbridge.com/en/quote/002727.CN.md)

## Related News & Research

- [Xinhua Pharma unit Xincat’s azithromycin tablets pass China generic consistency evaluation](https://longbridge.com/en/news/297485179.md)
- [07:00 ETInnovative Beverage Concepts Marks 30 Years of Premium Beverage Innovation Serving the Global Foodservice Industry](https://longbridge.com/en/news/297640635.md)
- [Sukano signs capacity reservation deal with Avantium for releaf PEF polymer](https://longbridge.com/en/news/297598025.md)
- [11:34 ETHUMAIN and Applied Intuition Announce Strategic Collaboration to Deploy Physical AI Across Saudi Arabia, Starting with Autonomous Trucking](https://longbridge.com/en/news/297540098.md)
- [H.U. Group unit Fujirebio wins Health Canada licenses for Lumipulse neurology blood tests](https://longbridge.com/en/news/297597814.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**